Should patients with chronic lymphocytic leukemia (CLL) receive the recombinant zoster vaccine (Shingrix) and what is the recommended dosing schedule?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Shingles Vaccine (Shingrix) in CLL Patients

Yes, patients with chronic lymphocytic leukemia (CLL) should receive the recombinant zoster vaccine (Shingrix/RZV), given as 2 doses at least 2-6 months apart, with a shorter 1-2 month interval allowed for high-risk adults. This recommendation applies to adults ≥50 years or adults ≥18 years at increased risk for zoster disease 1.

Key Recommendation Details

Dosing Schedule:

  • Standard schedule: 2 doses separated by 2-6 months 1
  • Accelerated schedule for high-risk patients: Second dose can be given 1-2 months after the first dose 1
  • If previously received live zoster vaccine (ZVL), RZV should be given at least 2 months after the last ZVL dose 1

Critical Safety Considerations

RZV is safe for CLL patients because it is a recombinant (non-live) vaccine - unlike the older live-attenuated zoster vaccine which was contraindicated in immunocompromised patients 1. Live vaccines remain contraindicated in CLL patients until at least 3 months after treatment discontinuation, and 6 months if anti-CD20 monoclonal antibodies were used 1.

Timing Optimization

Ideally vaccinate BEFORE starting CLL treatment whenever possible, as vaccine responses are significantly better in treatment-naive patients 1. The evidence shows:

  • Treatment-naive CLL patients: Better humoral response rates (approximately 51-59%) 1, 2
  • BTK inhibitor-treated patients: Lower response rates (approximately 32-41%) 1, 2
  • Anti-CD20 antibody exposure: Severely impairs vaccine response; consider postponing vaccination 6-12 months after last anti-CD20 dose if aiming for optimal protection 1

However, there are no safety concerns with vaccinating during treatment with BTK inhibitors or BCL-2 inhibitors 1. Even with suboptimal antibody responses, cellular immunity may still be elicited 1.

Expected Efficacy in CLL

Vaccine responses in CLL patients are significantly reduced compared to immunocompetent adults:

  • Only 29-45% achieve adequate antibody responses at 3 months post-vaccination 1, 2
  • T-cell responses occur in approximately 54% of CLL patients (lower than 96% in controls) 2
  • Combined antibody and cellular response: Only 29% of CLL patients 2
  • The humoral response rate in CLL patients is approximately 20% at one month and one year after the second dose in some studies 1

Despite these limitations, RZV is still recommended because:

  1. It provides the only available protection against herpes zoster in this high-risk population
  2. Even partial cellular immunity offers some protection
  3. CLL patients have significantly elevated risk of herpes zoster and its complications

Important Clinical Nuances

Continue antiviral prophylaxis in high-risk patients even after RZV vaccination, particularly those on BTK inhibitors or with history of prior herpes zoster reactivation 1. The guidelines explicitly state that until more data on long-term protection are available, acyclovir prophylaxis should continue in high-risk patient groups 1.

Factors associated with poor vaccine response:

  • Active treatment with BTK inhibitors (especially) or BCL-2 inhibitors 1, 2
  • Hypogammaglobulinemia 2
  • Prior intensive chemotherapy 1
  • Recent anti-CD20 antibody therapy 1
  • Concurrent antiviral prophylaxis during vaccination (in some studies) 3

Practical Implementation Algorithm

  1. At CLL diagnosis: Administer RZV before starting any therapy (optimal timing) 1

  2. If already on BTK/BCL-2 inhibitors: Still vaccinate - use accelerated 1-2 month schedule if desired 1

  3. If recent anti-CD20 therapy: Consider waiting 6-12 months for optimal response, but can vaccinate earlier if herpes zoster risk is high 1

  4. Maintain antiviral prophylaxis: Continue acyclovir/valacyclovir in high-risk patients regardless of vaccination status 1

  5. Consider antibody titer assessment: In BTK inhibitor-treated patients, checking titers and revaccination may be considered, though additional studies are needed 1

Common Pitfalls to Avoid

  • Do not withhold RZV because the patient is on active treatment - the vaccine is safe and may provide partial protection 1
  • Do not confuse RZV with the old live zoster vaccine - RZV is NOT contraindicated in immunocompromised patients 1, 4
  • Do not discontinue antiviral prophylaxis after vaccination in high-risk patients, as vaccine efficacy is uncertain 1
  • Do not delay vaccination indefinitely waiting for "perfect timing" - some protection is better than none in this high-risk population

References

Related Questions

For a 48‑year‑old man with newly diagnosed chronic lymphocytic leukemia who is up‑to‑date on influenza, COVID‑19, and tetanus‑pertussis vaccinations, which vaccine is most appropriate now: recombinant herpes‑zoster vaccine (Shingrix, recombinant zoster vaccine), meningococcal ACWY vaccine, or meningococcal B vaccine?
Which preventive vaccines are recommended for patients with chronic lymphocytic leukemia?
For an adult with chronic lymphocytic leukemia, which vaccine is most indicated—meningococcal vaccine or recombinant herpes zoster vaccine (Shingrix)?
Can Herpes Zoster (Varicella-Zoster Virus) or Human Papillomavirus (HPV) cause Chronic Lymphocytic Leukemia (CLL) or Non-Hodgkin Lymphoma (NHL)?
Which vaccinations are indicated for a 48-year-old man with newly diagnosed chronic lymphocytic leukemia who is already up-to-date on annual influenza vaccine, COVID‑19 boosters, and a recent tetanus‑pertussis booster?
Can bupropion (Wellbutrin) cause or worsen restless leg syndrome, and how should it be managed?
Can a person who has had Bell's palsy receive the shingles vaccine?
Should cholestyramine be used to treat cholelithiasis (gallstones)?
What is the maximum recommended daily dose of risperidone for a 7-year-old child with autism who experiences aggressive outbursts?
What is the dosing regimen of oral vancomycin for experimental treatment of inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC)?
How should I document the procedure for a left shoulder subacromial‑subdeltoid bursitis steroid injection, including patient identification, indication, informed consent, needle size, medication (methylprednisolone acetate and lidocaine), and post‑procedure care?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.